Related Experiment Video
Updated: May 15, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
FDA Advisory Committee Review of Supplemental Indications and Reasons for Non-Approval, 2008-2022
Audrey D Zhang1, Nikhil Chaudhry2, Reshma Ramachandran3
1Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.
Abstract:
This study characterizes 2008-2022 FDA advisory committee discussions of new supplemental indication applications that were not approved by FDA. Discussion themes included contextual concerns unique to already-approved drugs, including insights from prior experience and concerns about off-label use, and efficacy and safety concerns also observed for new drugs. These findings highlight advisory committees' role in transparency of regulatory decision-making, specifically for drugs already authorized for use.
Related Concept Videos
Drug Regulation
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinical Trials: Overview
Drug Control Governance: Regulatory Bodies and Their Impact
Preclinical Development: Overview
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

